Malaysia Biotech Industry Lags In Expected Growth
This article was originally published in PharmAsia News
Malaysia's experiment in building a biotechnology industry is lagging behind initial goals as the government approaches the second five-year phase set to begin in 2011. Plans call for the biotech industry to more than double its share of the economy to 2.5 percent within the 2011-2016 period. Since the National Biotechnology Policy was adopted in 2005, the biotech industry has grown only enough to constitute 1 percent of gross domestic product. The head of the government's Malaysia Biotechnology Corp said the nation needs more cooperation between researchers and industry players. (Click here for more
You may also be interested in...
Gilead clarifies position on Cipla’s sub-licensing effort for remdesivir, the investigational antiviral in the global spotlight as a potential treatment for COVID-19.
Discovered at record-breaking speed by AbCellera, Lilly says the antibody candidate could progress into Phase II trials by June.
While the COVID-19 pandemic continued to dominate EU-wide medtech decisions in May, further analysis of the one-year delay to the EU’s new regulations revealed some unexpected consequences. Meanwhile, a new flurry of documents and decisions have been produced by the European Commission.